Morphic Holding Inc (MORF)
27.79
-0.97
(-3.37%)
USD |
NASDAQ |
Jun 13, 16:00
27.79
0.00 (0.00%)
After-Hours: 19:36
Morphic Enterprise Value: 781.93M for June 12, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 12, 2024 | 781.93M |
| June 11, 2024 | 753.87M |
| June 10, 2024 | 806.47M |
| June 07, 2024 | 882.61M |
| June 06, 2024 | 872.09M |
| June 05, 2024 | 1.007B |
| June 04, 2024 | 870.09M |
| June 03, 2024 | 876.60M |
| May 31, 2024 | 862.58M |
| May 30, 2024 | 885.12M |
| May 29, 2024 | 849.05M |
| May 28, 2024 | 882.86M |
| May 24, 2024 | 884.12M |
| May 23, 2024 | 731.83M |
| May 22, 2024 | 806.97M |
| May 21, 2024 | 818.49M |
| May 20, 2024 | 864.58M |
| May 17, 2024 | 805.47M |
| May 16, 2024 | 966.77M |
| May 15, 2024 | 855.56M |
| May 14, 2024 | 761.89M |
| May 13, 2024 | 777.92M |
| May 10, 2024 | 774.91M |
| May 09, 2024 | 800.46M |
| May 08, 2024 | 810.48M |
| Date | Value |
|---|---|
| May 07, 2024 | 850.05M |
| May 06, 2024 | 861.57M |
| May 03, 2024 | 839.03M |
| May 02, 2024 | 779.42M |
| May 01, 2024 | 742.35M |
| April 30, 2024 | 707.29M |
| April 29, 2024 | 742.35M |
| April 26, 2024 | 747.36M |
| April 25, 2024 | 742.85M |
| April 24, 2024 | 728.33M |
| April 23, 2024 | 781.42M |
| April 22, 2024 | 768.90M |
| April 19, 2024 | 743.35M |
| April 18, 2024 | 719.31M |
| April 17, 2024 | 737.34M |
| April 16, 2024 | 736.34M |
| April 15, 2024 | 819.50M |
| April 12, 2024 | 776.92M |
| April 11, 2024 | 860.07M |
| April 10, 2024 | 844.04M |
| April 09, 2024 | 882.61M |
| April 08, 2024 | 848.55M |
| April 05, 2024 | 851.06M |
| April 04, 2024 | 849.55M |
| April 03, 2024 | 929.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
93.43M
Minimum
Mar 16 2020
2.525B
Maximum
Mar 01 2021
947.34M
Average
764.38M
Median
Nov 01 2022
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 18.77B |
| Cytokinetics Inc | 5.664B |
| Amicus Therapeutics Inc | 3.297B |
| Insmed Inc | 9.730B |
| Madrigal Pharmaceuticals Inc | 5.149B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.29M |
| Total Expenses (Quarterly) | 53.60M |
| EPS Diluted (Quarterly) | -0.91 |
| Earnings Yield | -12.59% |
| Normalized Earnings Yield | -5.901 |